Anna-Maria Fontrier is a Senior Researcher at the Medical Technology Research Group (MTRG), LSE Health. She has been involved in the management and research of numerous consultancy projects for both public and private sector on pharmaceutical policies, pricing, reimbursement, value assessment and access in Europe, Canada, Australia and the Middle East and North Africa region. She has participated in the research and coordination of IMPACT HTA European Union’s Horizon 2020 research and innovation programme. Past work experience includes junior roles at the Health Reform Support Program for Greece and Novartis Hellas.

Anna-Maria holds an MSc in International Health Policy from LSE and a BSc in Chemistry and Business Administration from Aston University. She is currently a PhD candidate at the Department of Health Policy at LSE, exploring implications of value assessment processes for the entry to market of new medicines and medicines treating rare diseases in the European Union, the United Kingdom and Canada.